skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 14,926  for All Library Resources

Results 1 2 3 4 5 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
02 Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity
Material Type:
Article
Add to My Research

02 Hydroxychloroquine myopathy: cardiac and skeletal muscle toxicity

Lupus science & medicine, 2021-04, Vol.8 (Suppl 1), p.A1-A2 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-la.2

Full text available

2
03 Low dose aspirin in aPL-positive patients: Are we treating the patient or the doctor?
Material Type:
Article
Add to My Research

03 Low dose aspirin in aPL-positive patients: Are we treating the patient or the doctor?

Lupus science & medicine, 2021-04, Vol.8 (Suppl 1), p.A2-A2 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-la.3

Full text available

3
04 Biology of interferons in SLE: insights from longitudinal data analysis
Material Type:
Article
Add to My Research

04 Biology of interferons in SLE: insights from longitudinal data analysis

Lupus science & medicine, 2021-04, Vol.8 (Suppl 1), p.A2-A3 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-la.4

Full text available

4
06 Microangiopathy in SLE: a diagnostic and therapeutic challenge
Material Type:
Article
Add to My Research

06 Microangiopathy in SLE: a diagnostic and therapeutic challenge

Lupus science & medicine, 2020-09, Vol.7 (Suppl 2), p.A4-A4 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2020-la.6

Digital Resources/Online E-Resources

5
1 H‐Magnetic Resonance Spectroscopy for Quantifying Myocardial Lipid Content in Humans With the Cardiometabolic Syndrome
Material Type:
Article
Add to My Research

1 H‐Magnetic Resonance Spectroscopy for Quantifying Myocardial Lipid Content in Humans With the Cardiometabolic Syndrome

The journal of clinical hypertension (Greenwich, Conn.), 2009-09, Vol.11 (9), p.528-532 [Peer Reviewed Journal]

ISSN: 1524-6175 ;EISSN: 1751-7176 ;DOI: 10.1111/j.1559-4572.2009.00061.x

Full text available

6
10 most common toxicoses in dogs
Material Type:
Article
Add to My Research

10 most common toxicoses in dogs

Veterinary medicine (1985), 2006-03, Vol.101 (3), p.142 [Peer Reviewed Journal]

COPYRIGHT 2006 Intellisphere, LLC ;Copyright Medical Economics Inc. Mar 2006 ;ISSN: 8750-7943 ;EISSN: 1939-1919

Digital Resources/Online E-Resources

7
10 simple but essential tests
Material Type:
Article
Add to My Research

10 simple but essential tests

Veterinary medicine (1985), 2008-06, Vol.103 (6), p.S10 [Peer Reviewed Journal]

COPYRIGHT 2008 Intellisphere, LLC ;Copyright Advanstar Communications, Inc. Jun 2008 ;ISSN: 8750-7943 ;EISSN: 1939-1919

Full text available

8
100 YEARS OF VITAMIN D: Supraphysiological doses of vitamin D changes brainwave activity patterns in rats
Material Type:
Article
Add to My Research

100 YEARS OF VITAMIN D: Supraphysiological doses of vitamin D changes brainwave activity patterns in rats

Endocrine Connections, 2022-03, Vol.11 (3) [Peer Reviewed Journal]

The authors 2022 The authors ;ISSN: 2049-3614 ;EISSN: 2049-3614 ;DOI: 10.1530/EC-21-0457 ;PMID: 35148281

Full text available

9
105 Non-traditional risk factors predict cardiovascular disease and contribute to disparities in a population-based cohort with systemic lupus erythematosus
Material Type:
Article
Add to My Research

105 Non-traditional risk factors predict cardiovascular disease and contribute to disparities in a population-based cohort with systemic lupus erythematosus

Lupus science & medicine, 2024-05, Vol.11 (Suppl 2), p.A5-A8 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2023-lupus21century.5

Full text available

10
11 guidelines for conservatively treating chronic kidney disease
Material Type:
Article
Add to My Research

11 guidelines for conservatively treating chronic kidney disease

Veterinary medicine (1985), 2007-12, Vol.102 (12), p.788-790 [Peer Reviewed Journal]

Copyright Advanstar Communications, Inc. Dec 2007 ;ISSN: 8750-7943 ;EISSN: 1939-1919

Full text available

11
11 guidelines for conservatively treating chronic kidney disease: you can prolong and improve the quality of life in dogs and cats suffering from this reduction in kidney function by monitoring and treating key parameters and signs
Material Type:
Article
Add to My Research

11 guidelines for conservatively treating chronic kidney disease: you can prolong and improve the quality of life in dogs and cats suffering from this reduction in kidney function by monitoring and treating key parameters and signs

Veterinary medicine (1985), 2007-12, Vol.102 (12), p.788 [Peer Reviewed Journal]

COPYRIGHT 2007 Intellisphere, LLC ;ISSN: 8750-7943 ;EISSN: 1939-1919

Full text available

12
1101 Use of popular opinion leader models to disseminate information about clinical trials to people of color with lupus in two U.S. cities
Material Type:
Article
Add to My Research

1101 Use of popular opinion leader models to disseminate information about clinical trials to people of color with lupus in two U.S. cities

Lupus science & medicine, 2021-11, Vol.8 (Suppl 2), p.A29-A29 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-lupus21century.44

Full text available

13
1105 Response Gene to Complement-32 expression is upregulated in the kidney and promotes renal fibrosis in lupus nephritis
Material Type:
Article
Add to My Research

1105 Response Gene to Complement-32 expression is upregulated in the kidney and promotes renal fibrosis in lupus nephritis

Lupus science & medicine, 2022-12, Vol.9 (Suppl 3), p.A71-A72 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2022-lupus21century.70

Full text available

14
1106 Stability of novel urinary biomarkers used for lupus
Material Type:
Article
Add to My Research

1106 Stability of novel urinary biomarkers used for lupus

Lupus science & medicine, 2022-12, Vol.9 (Suppl 3), p.A72-A73 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2022-lupus21century.71

Full text available

15
1114 Parenchymal INFγ Response Regulates Murine Lupus Nephritis in a PD-L1 Independent Fashion
Material Type:
Article
Add to My Research

1114 Parenchymal INFγ Response Regulates Murine Lupus Nephritis in a PD-L1 Independent Fashion

Lupus science & medicine, 2022-12, Vol.9 (Suppl 3), p.A79-A80 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2022-lupus21century.79

Full text available

16
1114 Trajectory of damage accrual in systemic lupus erythematosus based on ethnicity, socioeconomic factors and comorbidities
Material Type:
Article
Add to My Research

1114 Trajectory of damage accrual in systemic lupus erythematosus based on ethnicity, socioeconomic factors and comorbidities

Lupus science & medicine, 2021-11, Vol.8 (Suppl 2), p.A40-A40 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-lupus21century.57

Full text available

17
1115 RAIL biomarkers capture response to induction therapy in pediatric patients during induction therapy
Material Type:
Article
Add to My Research

1115 RAIL biomarkers capture response to induction therapy in pediatric patients during induction therapy

Lupus science & medicine, 2022-12, Vol.9 (Suppl 3), p.A80-A81 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2022-lupus21century.80

Full text available

18
1115 The type 1 & 2 SLE model: the perspective of patients and rheumatologists
Material Type:
Article
Add to My Research

1115 The type 1 & 2 SLE model: the perspective of patients and rheumatologists

Lupus science & medicine, 2021-11, Vol.8 (Suppl 2), p.A40-A41 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2021-lupus21century.58

Full text available

19
12 WEEKS OF PROGRESSIVE RESISTANCE TRAINING ON POSTURAL BALANCE AND CONCERNS ABOUT FALLING IN OLDER ADULTS: RANDOMIZED CONTROLLED TRIAL
Material Type:
Article
Add to My Research

12 WEEKS OF PROGRESSIVE RESISTANCE TRAINING ON POSTURAL BALANCE AND CONCERNS ABOUT FALLING IN OLDER ADULTS: RANDOMIZED CONTROLLED TRIAL

Motricidade, 2021-12, Vol.17 (4), p.1-21 [Peer Reviewed Journal]

2021. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. ;ISSN: 1646-107X ;EISSN: 2182-2972 ;DOI: 10.6063/motricidade.24977

Full text available

20
12 Management of lupus skin manifestations
Material Type:
Article
Add to My Research

12 Management of lupus skin manifestations

Lupus science & medicine, 2022-04, Vol.9 (Suppl 1), p.A6-A7 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;EISSN: 2053-8790 ;DOI: 10.1136/lupus-2022-la.12

Full text available

Results 1 - 20 of 14,926  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1967  (26)
  2. 1967 To 1981  (43)
  3. 1982 To 1994  (114)
  4. 1995 To 2008  (2,805)
  5. After 2008  (11,939)
  6. More options open sub menu

Language 

  1. English  (14,615)
  2. Japanese  (946)
  3. Spanish  (219)
  4. Portuguese  (76)
  5. Korean  (39)
  6. Chinese  (27)
  7. Norwegian  (17)
  8. Dutch  (8)
  9. French  (7)
  10. Polish  (3)
  11. Russian  (3)
  12. More options open sub menu

Searching Remote Databases, Please Wait